Seaport presents new meta-analysis examining the impact of clinical trial design factors on placebo response in generalized ...

- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

Please provide your email address to receive an email when new articles are posted on . Treatment of generalized anxiety disorder with an antidepressant increased the treatment response rate by 41%.

Findings showed the 100mcg dose met the primary endpoint demonstrating a statistically significant 7.6-point reduction in HAM-A score at week 4 compared with placebo. The Food and Drug Administration ...

All adults under age 65 should be screened for anxiety, according to the influential US Preventive Services Task Force, which issued new draft guidelines last month. The guidelines, which help guide ...